Gastric cancer
Not recruitingStudy of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy
Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy
- Disease:Gastric cancer
- Substances:DomvanalimabFluorouracil+3
France- Participants:18–64 years · 65+ years
- Substances:Domvanalimab
- Sponsor:Fondation Franc.Cancerologie Digestive
